Clinical Trial Update: An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

An extension study assessed the long-term safety and tolerability of one-month degarelix depots in prostate cancer, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Firmagon (Degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2010-12-14